| Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy TN Gide, C Quek, AM Menzies, AT Tasker, P Shang, J Holst, J Madore, ... Cancer cell 35 (2), 238-255. e6, 2019 | 624 | 2019 |
| Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 BlockadeTim-3 Blockade Reverses Melanoma NK-Cell Exhaustion IP da Silva, A Gallois, S Jimenez-Baranda, S Khan, AC Anderson, ... Cancer immunology research 2 (5), 410-422, 2014 | 378 | 2014 |
| Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L) 1 monotherapy: a multicentre, retrospective, cohort study IP da Silva, T Ahmed, ILM Reijers, AM Weppler, AB Warner, JR Patrinely, ... The Lancet Oncology 22 (6), 836-847, 2021 | 133 | 2021 |
| Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy I Pires da Silva, S Lo, C Quek, M Gonzalez, MS Carlino, GV Long, ... Cancer 126 (1), 86-97, 2020 | 130 | 2020 |
| Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma L Haas, A Elewaut, CL Gerard, C Umkehrer, L Leiendecker, M Pedersen, ... Nature Cancer 2 (7), 693-708, 2021 | 123 | 2021 |
| Serum‐based miRNAs in the prediction and detection of recurrence in melanoma patients NH Fleming, J Zhong, IP Da Silva, E Vega‐Saenz de Miera, B Brady, ... Cancer 121 (1), 51-59, 2015 | 106 | 2015 |
| Reversal of natural killer cell exhaustion by TIM-3 blockade A Gallois, I Silva, I Osman, N Bhardwaj Oncoimmunology 3 (12), e946365, 2014 | 102 | 2014 |
| Reversal of NK cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2014; 2: 5 410–22. doi: 10.1158/2326-6066 IP da Silva, A Gallois, SJ Baranda, S Khan, AC Anderson, VK Kuchroo CIR-13-0171, 0 | 86 | |
| Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance F Newell, IP da Silva, PA Johansson, AM Menzies, JS Wilmott, V Addala, ... Cancer cell 40 (1), 88-102. e7, 2022 | 81 | 2022 |
| Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients H Lee, C Quek, I Silva, A Tasker, M Batten, H Rizos, SY Lim, T Nur Gide, ... OncoImmunology 8 (2), e1537581, 2019 | 79 | 2019 |
| Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice IP Silva, GV Long Current opinion in oncology 29 (6), 484-492, 2017 | 79 | 2017 |
| New perspectives on the conservative management of osteoradionecrosis of the mandible: a literature review DA Costa, TP Costa, EC Netto, N Joaquim, I Ventura, AC Pratas, ... Head & neck 38 (11), 1708-1716, 2016 | 72 | 2016 |
| Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients TN Gide, IP Silva, C Quek, T Ahmed, AM Menzies, MS Carlino, RPM Saw, ... Oncoimmunology 9 (1), 1659093, 2020 | 68 | 2020 |
| Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant MelanomaGenetic Profile and Outcomes of V600E/V600K-Treated Melanoma I Pires da Silva, KYX Wang, JS Wilmott, J Holst, MS Carlino, JJ Park, ... Clinical Cancer Research 25 (4), 1272-1279, 2019 | 63 | 2019 |
| Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition A Rogiers, IP Da Silva, C Tentori, CA Tondini, JM Grimes, MH Trager, ... Journal for immunotherapy of cancer 9 (1), 2021 | 60 | 2021 |
| Comprehensive analysis of cutaneous and uveal melanoma liver metastases EP Hoefsmit, EA Rozeman, TM Van, P Dimitriadis, O Krijgsman, ... Journal for immunotherapy of cancer 8 (2), 2020 | 52 | 2020 |
| Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma I Pires da Silva, T Ahmed, JL McQuade, CA Nebhan, JJ Park, JM Versluis, ... Journal of Clinical Oncology 40 (10), 1068-1080, 2022 | 49 | 2022 |
| Analysis of recurrence patterns in acral versus nonacral melanoma: should histologic subtype influence treatment guidelines? PV Gumaste, NH Fleming, I Silva, RL Shapiro, RS Berman, J Zhong, ... Journal of the National Comprehensive Cancer Network 12 (12), 1706-1712, 2014 | 45 | 2014 |
| Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas C Quek, RV Rawson, PM Ferguson, P Shang, I Silva, RPM Saw, ... Oncotarget 10 (9), 930, 2019 | 41 | 2019 |
| Identification of a Novel Pathogenic Germline KDR Variant in MelanomaA Novel Pathogenic Germline Variant in Melanoma IP Silva, A Salhi, KM Giles, M Vogelsang, SW Han, N Ismaili, KP Lui, ... Clinical Cancer Research 22 (10), 2377-2385, 2016 | 40 | 2016 |
